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ABSTRACT 
The bioorganic synthesis of an end-capped anti-HIV peptide from a recombinant protein 
was investigated. Cyanogen bromide-mediated cleavage of two Met-Gln sites across the 
target anti-HIV sequence generated an HIV-1 fusion inhibitor (SC35EK) analog bearing an 
N-terminal pyroglutamate (pGlu) residue and a C-terminal homoserine lactone (Hsl) residue. 
The end-capped peptide, pGlu-SC35EK-Hsl, had similar bioactivity and biophysical 
properties to the parent peptide, and an improved resistance to peptidase-mediated 




Human immunodeficiency virus type 1 (HIV-1) is an enveloped virus that causes 
acquired immunodeficiency syndrome (AIDS) through the infection of immune cells. A 
number of anti-HIV drugs that target key enzymes in HIV-1 life cycle, including reverse 
transcriptase and viral protease, have been employed for highly active anti-retroviral therapy 
(HAART). Although combination therapy by HAART achieves prolonged viral suppression, 
resistant variants against these drugs often appear and compromise therapeutic efficiency.1 In 
order to manage this disease, novel anti-HIV drugs that target existing classes of molecules as 
well as newly identified molecules in the viral replication cycle have been developed, such as 
entry inhibitors and HIV-1 integrase inhibitors.2  
The fusion inhibitors are a new class of therapeutics for the treatment of HIV-1-infected 
patients. These drugs prevent viral entry into cells,3 which is mediated by the conformational 
transition of the viral envelope protein gp414 that occurs after gp120 binds to its receptors on 
the host cell surface. The ectodomain of gp41, with two heptad repeat regions, HR1 and HR2, 
is folded into an anti-parallel coiled-coil structure of fusion-active conformation. Synthetic 
peptides derived from gp41 HR2, such as T-20 (enfuvirtide) and C34, exert potent anti-HIV 
activity by interfering with this viral gp41 folding and, therefore, the subsequent membrane 
fusion process.5,6 The mode of interaction between an inhibitory HR2 peptide and the viral 
HR1, including a representative peptide N36, has been elucidated and exploited to design the 
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second-generation of fusion inhibitors.7 Previously, we developed the potent anti-HIV 
peptides, T-20EK and SC35EK, which were designed by rearrangement of the bioactive 
α-helix structure of T-20 and C34, respectively.8 Substitutions of the non-interactive residues 
within T-20 and C34 with hydrophilic glutamic acids or lysines improved the anti-HIV 
activity of the original peptides as well as their biophysical properties. 
T-20 is manufactured by chemical synthesis, in which a combination of solid-phase and 
solution-phase peptide synthesis methods is employed.9 Chemical synthesis of peptides 
allows optional modifications at the appropriate residues or positions by using 
non-proteinogenic amino acids and/or special amino acids with post-translational 
modifications which prolonged the effects of the peptide therapeutics in vivo. For example, 
N-terminal acyl- and/or C-terminal amide-modified peptides can be easily prepared, which 
can then contribute to the protection from enzymatic scissions that may occur in the 
circulatory system. However, step-wise elongation of a peptide-chain using protected amino 
acid components may be disadvantageous in terms of cost-effectiveness and environmental 
acceptability. The expression of recombinant proteins is an alternative approach used to 
prepare bioactive peptides and proteins,10 but the products are normally obtained without any 
functional modifications. Taking advantage of this approach, we synthesized an anti-HIV 
peptide, SC35EK, by a combination of the recombinant expression of fusion proteins in 
Escherichia coli and their subsequent treatment with chemical reagents to incorporate 
end-capping groups at both the N- and C-termini. 
Among the several cleavage reactions available for peptides and proteins, cyanogen 
bromide (CNBr)-mediated cleavage at methionine (Met) residues is one of the most 
conventional, and is used for both sequence analysis and for the preparation of bioactive, 
short peptides from insoluble recombinant fusion proteins in E. coli. Such proteins include 
antibiotic peptides,11 zinc finger peptides,12 insulin-like peptides13 and pH-responsive 
self-assembling peptides.14 It is noteworthy that CNBr-mediated cleavage releases the first 
fragment containing a cyclic homoserine lactone (Hsl) at the C-terminus,15 and the second 
fragment without any N-terminal functional group. This Hsl residue was designed as a 
C-terminal protecting group for SC35EK. Pyroglutamic acid (pGlu) was chosen as the 
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N-terminal protecting group as this residue is important for the physiological stability of 
several mammalian peptide hormones and proteins.16 The cyclic structure of pGlu can be 
obtained by cyclization from a glutamine (Gln) residue mediated either by glutaminyl cyclase 
in vivo, or by treatment of Gln in non-enzymatic conditions.16,17 
In this study, we undertook the bioorganic synthesis of an SC35EK analog, which 
contains cyclic N-terminal pGlu and C-terminal Hsl end-capping structures.18 Using a model 
synthetic peptide, the conditions necessary for the cleavage and cyclization of a Gln residue to 
a pGlu residue were optimized. Recombinant His-tag fusion proteins containing either a 
single, or three consecutive anti-HIV sequences were expressed and purified from E. coli. The 
peptide, pGlu-SC35EK-Hsl, was cleaved from the resulting recombinant protein under 
optimized acidic conditions. We then assessed the biological and biophysical characteristics of 
pGlu-SC35EK-Hsl and its biostability in mouse serum. 
 
2. Results and discussion 
2.1. Cleavage and cyclization of the model synthetic peptide 
In order to obtain the end-capped SC35EK protein, we incorporated two Met-Gln 
dipeptide cleavage sites across the anti-HIV SC35EK sequence. A CNBr-mediated cleavage 
should provide a C-terminal Hsl residue and an N-terminal Gln residue, which could then be 
converted into pGlu under mildly acidic conditions. Using a model synthetic peptide 
Ac-MQ-WEEWDKK-MQ-OH (MQ-SC7EK-MQ) 1 derived from the N-terminal sequence of 
SC35EK, the acidic conditions for CNBr-mediated cleavage and cyclization were optimized 
(Scheme 1). The reaction products were analyzed using LC–MS and the yields of 
Gln-SC7EK-Hsl 2 and pGlu-SC7EK-Hsl 3 were calculated based upon the peak areas at 220 
nm (Table 1). The pGlu formation was verified by the comparative analysis with the authentic 
sample obtained by chemical synthesis using pyroglutamic acid. CNBr-mediated cleavage of 
peptide 1 in the standard 70% formic acid (FA) solution yielded Gln-SC7EK-Hsl 2 without 
the oxidation of Met residues (entry 1). Significant Met oxidation, which disrupted the 
cleavage reaction, was observed under the other acidic conditions, including 30% FA, 0.1 N 
HCl, 0.1 M trifluoroacetic acid (TFA) and 0.1 N AcOH. This by-product formation was 
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prevented by the addition of tris(2-carboxyethyl)phosphine (TCEP) (entries 2–5). Partial 
production of the expected pGlu derivative 3 was observed in all cases in which this 
cyanylation step was carried out. The second cyclization, from N-terminal Gln to pGlu, was 
completed within 2 h. However, when 0.1 N AcOH solution was used, the reaction was 
incomplete (Fig. 1). Small amounts of formylated by-product were obtained along with 
peptide 3 in 70% FA solution, but peptide 3 was produced in higher yield (entry 1). 
 
2.2. Preparation of recombinant His-tagged fusion protein 
We used the pET28a(+) vector to express a hexa-histidine tagged [His-tag, 
(His)6]-fusion protein in E. coli. The MQ-SC35EK-MQ sequence, or the tandem 
M-(Q-SC35EK-M)3-Q sequence was spliced into the NdeI-XhoI restriction site downstream 
of the His-tag. This tandem sequence contains three consecutive anti-HIV peptides with five 
conjunctive Met-Gln cleavage sites designed to efficiently provide multiple SC35EK peptides 
from a single protein. Constructs were transformed into the E. coli strain BL21 (DE3)-RIL 
and protein expression was induced by IPTG. The resulting proteins were purified by affinity 
chromatography using Ni2+-nitrilotriacetate (Ni-NTA)-agarose resin, and the expected 
proteins were eluted with either a standard imidazole buffer or an acidic solution containing 
70% FA, 0.1 N HCl or 0.1 M TFA. After elution using imidazole, the remaining imidazole 
was removed by gel-filtration. The sizes of the (His)6-MQ-SC35EK-MQ 4 or 
(His)6-M-(Q-SC35EK-M)3-Q 5 fusion proteins on SDS–PAGE gels were 7.0 and 16.5 kDa, 
respectively (Fig. 2). 
The (His)6-MQ-SC35EK-MQ protein 4 was highly expressed in the soluble fraction and 
was obtained by elution with either imidazole or above acidic solutions from the affinity 
chromatography resin (Fig. 2a). Using the standard imidazole protocol, protein 4 was eluted 
in a moderate yield, however, approximately 100 mg of 4 was recovered from 1 L of bacterial 
culture under acidic solutions (Table 2). The lower yield obtained after elution using 
imidazole may be attributable either to incomplete protein elution from the column and/or 
protein loss during the desalting process. The purity of the (His)6-MQ-SC35EK-MQ 4 was 
confirmed as >95% by HPLC (Fig. 4a). (His)6-M-(Q-SC35EK-M)3-Q 5 was expressed in both 
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the soluble and insoluble fractions (Fig. 2b) and this resulted in a decreased yield, regardless 
of the high expression level seen in the total fraction. Consequently, only 19 or 26 mg/L of 
protein 5 was obtained by elution with imidazole or acidic solutions, respectively, (including 
70% FA, 0.1 N HCl, or 0.1 M TFA), with <80% purity confirmed by HPLC. Thus, 
(His)6-MQ-SC35EK-MQ 4 was used for the further experiments. 
 
2.3. Production of the anti-HIV peptide by cleavage and cyclization of the recombinant 
protein 
The optimized cleavage protocol established above was applied to 
(His)6-MQ-SC35EK-MQ 4. Purified protein 4 was cleaved and cyclized simultaneously by 
CNBr treatment under acidic conditions at 60 ºC for 2 h (Scheme 2, and Fig. 3). All the 
LC–MS profiles indicated the formation of two major products corresponding to the tag 
fragment 6 and pGlu-SC35EK-Hsl 7 (Fig. 4b, top). The formylated by-products of 6 and 7 
were only obtained by reaction in 70% FA. This result agrees with that obtained using the 
model peptide, and also with previous reports.15b Significant amounts of ring-opened products 
at the C-terminal Hsl of 6 and 7 were observed when the cleavage reaction was carried out in 
either 0.1 N HCl or 0.1 M TFA (Fig. 4b, middle and bottom). pGlu-SC35EK-Hsl 7 obtained 
under all conditions was purified by HPLC with >99% purity (Fig. 4c). Peptide 7 was 
characterized by ESI-MS measurement and by the comparative analysis with the one obtained 
by chemical synthesis using pGlu (see Supplementary data). The cyclization yields of 
pGlu-SC35EK-Hsl 7 obtained from the reaction in 70% FA, 0.1 N HCl, or 0.1 M TFA 
solutions were 16%, 15%, and 14%, respectively, and the overall yields from 1 L of E. coli 
culture were 10.4 mg, 10.2 mg, and 8.7 mg, respectively (Table 2).  
 
2.4. Analysis of the SC35EK analog with end-capping groups by circular dichroism 
The peptide conformation of pGlu-SC35EK-Hsl 7 was evaluated by measurement of the 
CD spectrum, along with SC35EK 8 and the non-end-capped peptide 9 (Fig. 5a, Table 3).19 
SC35EK 8 exhibits an α-helical conformation and interacts directly with an NHR-derived 
peptide, N36.8a The similar spectra with two characteristic spectrum minima at 208 and 222 
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nm were observed for peptides 7 and 8. Peptide 9 showed significantly less α-helix formation 
compared with the other peptides, suggesting that the improved α-helical conformation of 
SC35EK is affected by the presence of the capping groups, but not by their structure. Potential 
six-helical bundle structure formation consisting of SC35EK derivatives 7–9 and N36, and the 
stability of the peptides, were also evaluated using CD analysis. The similar, stabilized 
α-helix conformations were verified within three complexes of six-helical bundle structures 
by the CD spectra (Fig. 5b). However, the thermal stability of the peptide 9-N36 was less than 
those of the other two complexes [Tm(7) = 73.6 °C; Tm(8) = 75.8 °C; Tm(9) = 62.5 °C] (Fig. 5c 
and Table 3).  
 
2.5. Anti-HIV activity 
The anti-HIV activity of the SC35EK-derived peptides was evaluated using the MAGI 
assay (Table 3). pGlu-SC35EK-Hsl 7 reproduced the anti-HIV activity of SC35EK 8 [EC50(7) 
= 0.57 nM; EC50(8) = 0.50 nM], indicating that the original anti-HIV activity is not disrupted 
by the presence of the N- and C-terminal end-capping functional groups derived from the 
Met-Gln cleavage sites. The fivefold reduction in anti-HIV activity exhibited by peptide 9 
compared with two other peptides was consistent with the less stable α-helix structures, both 
in the peptide itself and in the six-helical bundle complex.  
 
2.6. Stability of the end-capped peptide in mouse serum 
The ability of the N- and C-terminal capping moieties to protect the SC35EK analog 7 
from biodegradation was assessed by incubating the peptides in mouse serum (Fig. 6). Rapid 
degradation of the non-end-capped peptide 9 was observed. Although pGlu-SC35EK-Hsl 7 
was more stable than peptide 9, ring-opening of the C-terminal Hsl in this peptide, followed 
by degradation at the C-terminus was observed.20 This suggests that the pGlu end-capping 
group is able to provide protection equivalent to that of an N-terminal acyl group. The 
γ-lactone structure of the C-terminal Hsl may be unfavorable for in vivo biostability compared 





The bioorganic synthesis of an end-capped anti-HIV peptide was achieved. The 
CNBr-mediated cleavages at the Met-Gln dipeptide sites of recombinant protein 4 afforded 
the end-capped SC35EK analog 7 bearing an N-terminal pGlu residue and a C-terminal Hsl 
residue. The acidic solution used for elution from the affinity chromatography resin to obtain 
the purified recombinant protein was also used for the cleavage-cyclization reactions. This 
facilitated the synthetic process and removed the need for repeated purifications to obtain 
peptide 7 in high yield. The resulting end-capped peptide 7 exhibited a stable α-helical 
conformation, anti-HIV activity equipotent to the parent peptide 8 and was resistant to 
biodegradation in serum when compared with the non-end-capped peptide 9. The methods 
outlined in this paper are directly applicable to the preparation of end-capped anti-HIV fusion 
inhibitors from recombinant proteins, which may provide the next generation of therapeutic 




For HPLC separations of synthetic peptides, a Cosmosil 5C18-ARII analytical column 
(4.6 x 250 mm, flow rate 1 mL/min, Nacalai Tesque, Kyoto, Japan) or a Cosmosil 5C18-ARII 
preparative column (20 x 250 mm, flow rate 10 mL/min) was employed. The eluting products 
were detected by UV at 220 nm. A solvent system consisting of 0.1% TFA solution (v/v, 
solvent A) and 0.1% TFA in MeCN (v/v, solvent B) were used for HPLC elution.  
 
4.2 Peptide synthesis.  
Protected peptide-resins were manually constructed by standard Fmoc-based SPPS on 
Rink amide resin (Novabiochem, 83 mg, 0.05 mmol). t-Bu for Tyr, Ser and Thr; t-Bu ester for 
Asp and Glu; Boc for Lys; and Trt for Asn and Gln were employed for side-chain protection, 
respectively. Fmoc-amino acids were coupled using five equivalents of reagents [Fmoc-amino 
acid, N,N'-diisopropylcarbodiimide and HOBt·H2O] to free amino group in DMF for 1.5 h. 
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Fmoc deprotection was performed by 20% piperidine in DMF (2 x 1 min, 1 x 20 min). The 
resulting protected resin was treated with TFA/H2O/m-cresol/thioanisole/1,2-ethandithiol 
(80:5:5:5:5) at room temperature for 2 h. After removal of the resin by filtration, ice-cold dry 
Et2O (30 mL) was added to the residue. The resulting powder was collected by centrifugation 
and then washed with ice-cold dry Et2O (3 x 15 mL). Purification of the crude product by 
preparative HPLC afforded a colorless powder of the desired peptide. All peptides were 
characterized by an ESI-MS (micromassZQ2000, Waters), and the purity was calculated as 
>95% by HPLC. 
 
4.3. Cleavage and cyclization of the model peptide 
The model synthetic peptide MQ-SC7EK-MQ 1 was treated with CNBr (100 equiv) in 
the presence of TCEP (10 equiv) under acidic conditions at room temperature for 2 h. After 
cleavage at the Met residue, the reaction mixture was heated at 60 °C for 2 h. The reaction 
products were analyzed every 30 min using LC–MS (Fig. 1). The Gln-SC7EK-Hsl 2 or the 
pGlu-SC7EK-Hsl 3 peptides were quantified based on the combined peak areas at 220 nm of 
peptides after HPLC. 
 
4.4. Preparation of recombinant (His)6-fused proteins. 
The cDNA sequences encoding the MQ-SC35EK-MQ or M-(Q-SC35EK-M)3-Q 
proteins were amplified by PCR using the following chemically synthesized 139-mer or 
361-mer oligonucleotides, respectively: 
5'-ctcCATATGCAGTGGGAAGAATGGGATAAAAAAATTGAAGAATATACCAAA
AAAATTGAAGAACTGATTAAAAAATCGGAAGAACAGCAAAAAAAAAATGAAGAA
GAACTGAAAAAAATGCAGTAACTCGAGcgtt-3' (both end of sequences in small letters 
indicate a flanking sequence for efficient restriction enzyme digestion of NdeI (CATATG) and 








ATGAGGAAGAATTGAAGAAAATGCAATAACTCGAGcgtt-3' (both end of sequences in 
small letters indicate a flanking sequence for efficient restriction enzyme digestion of BamHI 
(GGATCC), NdeI (CATATG) and XhoI (CTCGAG)). 
Codons were replaced by more frequently used ones based on E. coli codon usage. The 
synthetic cDNA fragments contained NdeI and XhoI restriction sites at the 5' and 3' ends, 
respectively, and an extra ATGCAG or ATGCAA sequence (encoding Met-Gln, underlined) at 
their 5' and 3' termini across the SC35EK sequence to facilitate cleavage and cyclization. 
Each segment was digested with NdeI and XhoI and inserted into the pET28a (+) vector 
(Novagen). The plasmids [pET28a-MQ-SC35EK-MQ or pET28a-M(Q-SC35EK-M)3-Q] were 
then transformed into the E. coli strain BL21(DE3)-RIL (Stratagene) for expression. Isolated 
colonies were picked and cultured overnight in 10 mL of LB culture containing 0.100 mg/mL 
kanamycin at 30 °C, with shaking. This culture was then transferred into 1 L of LB culture in 
the presence of 0.100 mg/mL kanamycin. When the OD600 reached 0.6–0.8, protein 
expression was initiated by the addition of 1 mM IPTG. After an additional 6-h incubation at 
25 °C, the cells were harvested by centrifugation at 4000 rpm for 30 min. Cells were 
resuspended in B-PER solution (PIERCE) and disrupted by sonication. After centrifugation at 
12,000 rpm for 30 min, the supernatant was transferred to a Ni-NTA agarose column 
(QIAGEN). The column was washed with wash buffer (20 mM phosphate, pH 6.0, containing 
0.5 M NaCl) and the protein eluted with imidazole buffer (50–200 mM imidazole in 
phosphate buffer (pH 6.0)), 70% FA, 0.1 N HCl or 0.1 M TFA. The expression and 
purification of the proteins was analyzed by SDS–PAGE (15–20% gradient gel). The protein 
eluted with imidazole buffer was desalted by gel-filtration and freeze-dry. The freeze-dried 
protein was reconstituted in water to a concentration of 1 mM. The yield of the eluted proteins 
was calculated using a Protein Assay Kit (BIO-RAD Laboratories, Hercules, CA). 
 
4.5. Preparation of the end-capped anti-HIV peptide from the recombinant protein.  
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The protein eluted with an acidic solution was reconstituted to a concentration of 1 mM. 
The protein was treated with CNBr (100 equiv) in the presence of TCEP (10 equiv) under 
acidic conditions (as shown in Table 2) at 60 °C for 2 h and the products were analyzed by 
LC–MS. Preparative HPLC of the product provided the expected end-capped peptide. The 
yield of purified peptide was calculated by measuring the UV absorbance at 280 nm. 
 
4.6. Measurement of CD spectra.  
Peptides 7–9 were dissolved in 5 mM HEPES buffer (pH 7.2) to a final concentration of 
10 µM. For CD measurement of a mixture of the NHR peptide (N36) and SC35EK analogs, 
the peptides were incubated at 37 °C for 30 min beforehand. The wavelength-dependent 
molar ellipticity [θ] was monitored at 25 ºC as the average of 8 scans in a Jasco 
spectropolarimeter (Model J-710, Jasco Inc., Tokyo, Japan). Thermal unfolding of the 
potential six-helical bundle in the presence of N36 was monitored by the [θ]222 values at 
intervals of 0.5 °C after a 15-s equilibration at the desired temperature and an integration time 
of 1.0 s. The midpoint of the thermal unfolding transition of each complex was defined as the 
melting temperature (Tm). 
 
4.7. Determination of drug susceptibility of HIV-1.  
The peptide sensitivity of infectious clones was determined by the MAGI assay with 
some modifications.21 Briefly, the target cells (HeLa-CD4/CCR5-LTR-β-gal; 104 cells/well) 
were plated in 96-well flat microtiter culture plates. On the following day, the cells were 
inoculated with the HIV-1 clone (NL4-3, 60 MAGI U/well, giving 60 blue cells after 48 h of 
incubation) and cultured in the presence of various concentrations of drugs in fresh medium. 
After (48 h) viral exposure, all the blue cells stained with X-Gal 
(5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside) were counted in each well. The activity 
of test compounds was determined as the concentration that blocked HIV-1 replication by 
50% (50% effective concentration [EC50]). 
 
4.8. Stability of SC35EK peptide or analogs in mouse serum. 
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Peptides 7–9 (0.5 mM in PBS) were incubated at 37 °C in 50% mouse serum in the 
presence of 0.1% m-cresol (internal standard). 0.010 mL samples were collected at 0, 0.5, 1, 3, 
6, 9 and 12 h and the reaction was terminated by the addition of 1 µL 0.1 N HCl and 0.040 
mL of CH3CN. Samples were deproteinized by centrifugation at 12,000 rpm for 10 min and 
0.010 mL of the supernatant was injected into LC–MS. The percentage of intact peptides was 
calculated by peak area and corrected against the internal standard. 
 
Acknowledgements 
This work was supported by Science and Technology Incubation Program in Advanced 
Regions from Japan Science and Technology Agency, and Health and Labour Sciences 
Research Grants (Research on HIV/AIDS). 
 
Supplementary data 
Supplementary data associated with this article can be found, in the online version, 
at doi:10.1016/j.bmc.2009.10.017. 
 13 
References and notes 
1. Richman, D. D.; Morton, S. C.; Wrin, T.; Hellmann, N.; Berry, S.; Shapiro, M. F.; 
Bozzette, S. A. AIDS. 2004, 18, 1393. 
2. For a review, see: Flexner, C. Nat. Rev. Drug Discov
3. Chan, D. C.; Kim, P. S. Cell. 1998, 93, 981. 
. 2007, 6, 959. 
4. Eckert, D. M.; Kim, P. S. 
5. (a) Wild, C.; Oas, T.; McDanal, C.; Bolognesi, D.; Matthews, T. 
Annu. Rev. Biochem. 2001, 70, 777. 
Proc. Natl. Acad. Sci. U 
S A. 1992, 89, 10537; (b) Wild, C.; Greenwell, T.; Matthews, T. AIDS Res. Human 
Retrovirus. 1993, 9, 1051; (c) Wild, C. T.; Shugars, D. C.; Greenwell, T. K.; McDanal, C. 
B.; Matthews, T. J. 
6. For a review, see: Matthews, T.; Salgo, M.; Greenberg, M.; Chung, J.; DeMasi, R.; 
Bolognesi, D. 
Proc. Natl. Acad. Sci. U S A. 1994, 91, 9770.  
Nat. Rev. Drug Discov
7. (a) Izumi, K.; Kodama, E.; Shimura, K.; Sakagami, Y.; Watanabe, K.; Ito, S.; Watabe, T.; 
Terakawa, Y.; Nishikawa, H.; Sarafianos, S. G.; Kitaura, K.; Oishi, S.; Fujii, N.; Matsuoka, 
M.
. 2004, 3, 215. 
 J. Biol. Chem. 2009, 284, 4914; (b) Watabe, T.; Terakawa, Y.; Watanabe, K.; Ohno, 
H.; Nakano, H.; Nakatsu, T.; Kato, H.; Izumi, K.; Kodama, E.; Matsuoka, M.; Kitaura, 
K.; Oishi, S.; Fujii, N. J. Mol. Biol
8. (a) Otaka, A.; Nakamura, M.; Nameki, D.; Kodama, E.; Uchiyama, S.; Nakamura, S.; 
Nakano, H.; Tamamura, H.; Kobayashi, Y.; Matsuoka, M.; Fujii, N. 
. 2009, 392, 657. 
Angew. Chem., Int. 
Ed. 2002, 41, 2937; (b) Oishi, S.; Ito, S.; Nishikawa, H.; Watanabe, K.; Tanaka, M.; Ohno, 
H.; Izumi, K.; Sakagami, Y.; Kodama, E.; Matsuoka, M.; Fujii, N. J. Med. Chem. 2008, 
51, 388; (c) Nishikawa, H; Oishi, S.; Fujita, M.; Watanabe, K.; Tokiwa, R.; Ohno, H.; 
Kodama, E.; Izumi, K.; Kajiwara, K.; Naitoh, T.; Matsuoka, M.; Otaka, A.; Fujii, N. 
Bioorg. Med. Chem. 2008, 16, 9184; (d) Nishikawa, H.; Nakamura, S.; Kodama, E.; Ito, 
S.; Kajiwara, K.; Izumi, K.; Sakagami, Y.; Oishi, S.; Ohkubo, T.; Kobayashi, Y.; Otaka, 
A.; Fujii, N.; Matsuoka, M. Int. J. Biochem. Cell Biol. 2009, 41, 891; (e) Naito, T.; Izumi, 
K.; Kodama, E.; Sakagami, Y.; Kajiwara, K.; Nishikawa, H.; Watanabe, K.; Sarafianos, S. 
G.; Oishi, S.; Fujii, N.; Matsuoka, M. Antimicrob. Agents Chemother
9. Bray BL. Nat. Rev. Drug. Discov. 2003, 2, 587. 
. 2009, 53, 1013. 
 14 
10. Dingermann, T. Biotechnol. J. 2008, 3, 90. 
11. (a) Rao, X. C.; Li, S.; Hu, J. C.; Jin, X. L.; Hu, X. M.; Huang, J. J.; Chen, Z. J.; Zhu, J. 
M.; Hu, F. Q. Protein Expr. Purif. 2004, 36, 11; (b) Park, T. J.; Kim, J. S.; Choi, S. S.; 
Kim, Y. Protein Expr. Purif. 2009, 65, 23; 
12. Zhao, D. X.; Ding, Z. C.; Liu, Y. Q.; Huang, Z. X. Protein Expr. Purif. 2007, 53, 232. 
(c) Zorko, M.; Japelj, B.; Hafner-Bratkovic, I.; 
Jerala, R. Biochim. Biophys. Acta. 2009, 1788, 314. 
13. Chang, S. G.; Kim, D. Y.; Choi, K. D.; Shin, J. M.; Shin, H. C. Biochem. J. 1998, 329, 
631. 
14. Riley, J. M.; Aggeli, A.; Koopmans, R.J.; McPherson, M. J. Biotech. Bioeng. 2009, 103, 
241. 
15. (a) Gross, E.; Witkop, B. J. Biol. Chem. 1962, 237, 1856; (b) Kaiser, R.; Metzka, L. Anal. 
Biochem. 1999, 266, 1.  
16. Abraham, G. N.; Podell, D. N. Mol. Cell. Biochem. 1981, 38, 181. 
17. (a) Schilling, S.; Hoffmann, T.; Rosche, F.; Manhart, S.; Wasternack, C.; Demuth, H. U.  
Biochemistry, 2002, 41, 10849; (b) Fernández, G. A.; Butz, P.; Trierweiler, B.; Zöller, H.; 
Stärke, J.; Pfaff, E.; Tauscher, B. J Agric. Food Chem. 2003, 51, 8093; (c) Chelius, D.; 
Jing, K.; Lueras, A.; Rehder, D. S.; Dillon, T. M.; Vizel, A.; Rajan, R. S.; Li, T.; Treuheit, 
M. J.; Bondarenko, P. V. Anal. Chem. 2006, 78, 2370. 
18. Recently, we have reported the preparation of HIV fusion inhibitor SC34EK by an 
alternative cleavage reaction using 1-cyano-4-dimethylaminopyridinium tetrafluoroborate 
(CDAP) for the Cys residues: Tanaka, M.; Kajiwara, K.; Tokiwa, R.; Watanabe, K.; Ohno, 
H.; Tsutsumi, H.; Hata, Y.; Izumi, K.; Kodama, E.; Matsuoka, M.; Oishi, S.; Fujii 
19. Non-end capped peptide 9 can be obtained by standard recombinant expression in 
prokaryotes. Peptide 9 for this experiment was obtained by the chemical synthesis. 
N, 
Bioorg. Med. Chem. 2009, 17, 7487. 
20. The ring-opening C-terminal Hsl was verified by the observed +18 mass of the product, 
supporting the presence of Hsl in peptide 715
21. (a) Maeda, Y.; Venzon, D. J.; Mitsuya, H. J. Infect. Dis., 1998, 177, 1207; (b) Kodama, E. 
. The ring-opened product may be degraded 
from the C-terminus by endopeptidases in serum. 
 15 
I.; Kohgo, S.; Kitano, K.; Machida, H.; Gatanaga, H.; Shigeta, S.; Matsuoka, M.; Ohrui, 
H.; Mitsuya, H. Antimicrob. Agents. Chemother. 2001, 45, 1539. 
 16 
Table 1. Cleavage and cyclization reactions of a model synthetic peptide, MQ-SC7EK-MQ 1, 
under acidic conditions. 
   yield by CNBr treatment (%)a,c yield of pGlu formation (%)b,c 
entry solvent additive 2 3 2 3 
1 70% FA - 78.3 2.4 - 70.7 
2 30% FA TCEP 60.5 5.7 - 57.7 
 3 0.1 N HCl TCEP 63.8 5.8 4.5 60.0 






5 0.1 N AcOH TCEP 53.9 3.6 16.9 37.0 
a CNBr treatment (100 equiv.) was carried out for 2 h at room temperature. b All cyclizations 
were carried out for 2 h at 60 °C. c The yields were calculated based on the combined peak 
areas of the peptides at 220 nm after HPLC. 
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Table 2. Purification of proteins 4 and 5 by affinity chromatography and the subsequent 
CNBr-mediated cleavage and cyclization reactions of 4. 
  protein yield from 1 L 
culture (mg)a cyclization yield of 
7 from 4 (%)b,c 
overall yield from 1 
L culture of 4 (mg) d entry solvent 4 5 
1 imidazole 35 19 -e -e 
2 70% FA 92 26 16 10.4 
3 0.1 N HCl 100 26 15 10.2 
 4 0.1 M TFA 94 26 14 8.7 
 a The yield was quantified using Bradford protein assay. b CNBr treatment (100 equiv.) and 
cyclization were carried out for 2 h at 60 °C. c The yield was quantified by UV absorbance at 
280 nm. d Peptide yields (mg) from 1 L culture of 4. e Not tested. 
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Table 3. Structures and anti-HIV activity of peptides 7-9. 
R1-WEEWDKKIEEYTKKIEELIKKSEEQQKKNEEELKK-R2  









0.57 ± 0.24 73.6 
SC35EK 8 Ac NH2 0.50 ± 0.16 75.8 
9 H OH 2.43 ± 0.22 62.5 
a EC50 was determined as the concentration that blocked HIV-1 infection by 50% in the 
MAGI assay.  
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Figure 1. Time course of the cyclization process from Gln-SC7EK-Hsl to pGlu-SC7EK-Hsl. 
Cyclization of Gln to pGlu by heating the reaction at 60 ºC under acidic conditions was 
monitored every 30 min for 2 h. The yields were calculated based on the combined peak areas 




Figure 2. SDS-PAGE of recombinant proteins. (a) (His)6-MQ-SC35EK-MQ 4 (7.0 kDa) and 
(b) (His)6-M-(Q-SC35EK-M)3-Q 5 (16.5 kDa). Lane Mk: molecular weight markers; lane 1: 
whole cell lysate; lane 2: supernatant of cell lysate; lane 3: precipitation of cell lysate; lane 4: 
pre-eluted resin; lanes 5-8: purified fractions from imidazole solution, 70% FA, 0.1 N HCl or 





Figure 3. SDS-PAGE analysis of cleavage products and purified proteins. Lane Mk: 
polypeptide molecular weight marker; lanes 1, 4 and 7: (His)6-MQ-SC35EK-MQ 4 (7.0 kDa); 
lanes 2, 5 and 8: after CNBr-mediated cleavage; lanes 3, 6 and 9: after HPLC purification; 
lane PC: chemically synthesized pGlu-SC35EK-Hsl 7 (control). 
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Figure 4. HPLC profiles of (a) (His)6-MQ-SC35EK-MQ protein 4; (b) the products of 
CNBr-mediated cleavage in (top) 70% FA, (middle) 0.1 N HCl, (bottom) 0.1 M TFA; (c) 
purified peptide 7. Asterisk indicates the mono-formylated products of 6 and 7. Inverted 
triangle indicates the ring-opened products at the Hsl of 6 and 7, HPLC conditions: linear 
gradient 10-60% solvent B in solvent A over 50 min. 
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Figure 5. Secondary structure analysis using CD spectroscopy: CD spectra of (a) 
SC35EK-derived peptide; (b) SC35EK analog-N36 complex; and (c) thermostability of the 
SC35EK analog-N36 complex. 
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Figure 6. Degradation profile of peptides 7–9 by mouse serum. Each bar shows the mean ± 














An anti-HIV peptide with N- and C-terminal end-capping groups was synthesized by 
cyanogen bromide-mediated cleavage of a recombinant protein. 
 
